Matthew James Farrer

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Glucosidase-beta variations and Lewy body disorders
    Matthew J Farrer
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
    Parkinsonism Relat Disord 15:414-6. 2009
  2. ncbi In vivo silencing of alpha-synuclein using naked siRNA
    Jada Lewis
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Mol Neurodegener 3:19. 2008
  3. ncbi Genetic association study of synphilin-1 in idiopathic Parkinson's disease
    Ronny Myhre
    Department of Laboratory Medicine, Children s and Women s Health, Norwegian University of Science and Technology, Trondheim, Norway
    BMC Med Genet 9:19. 2008
  4. ncbi Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications
    Matt Farrer
    Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Ann Neurol 55:174-9. 2004
  5. ncbi LRRK2 mutations in Parkinson disease
    M Farrer
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Neurology 65:738-40. 2005
  6. ncbi Genetics of Parkinson disease: paradigm shifts and future prospects
    Matthew James Farrer
    Morris K Udall Parkinsons Disease Research Center of Excellence, Birdsall Building, Mayo Clinic, Department of Neuroscience, 4500 San Pablo Road, Jacksonville, Florida 32224, USA
    Nat Rev Genet 7:306-18. 2006
  7. ncbi DCTN1 mutations in Perry syndrome
    Matthew J Farrer
    Division of Neurogenetics, Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, USA
    Nat Genet 41:163-5. 2009

Research Grants

  1. Mapping a Gene for Parkinsons Disease in Norway
    Matthew Farrer; Fiscal Year: 2005
  2. Genetic Analysis of Tau H1 in Parkinsonism
    Matthew Farrer; Fiscal Year: 2006

Collaborators

Detail Information

Publications7

  1. ncbi Glucosidase-beta variations and Lewy body disorders
    Matthew J Farrer
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
    Parkinsonism Relat Disord 15:414-6. 2009
    ..0 (95% CI: 0.3-29, p=0.3). All three affected carriers were classified as diffuse Lewy body disease (n=3/50; 6%). Our study suggests glucosidase-beta variants have a limited role in susceptibility to Lewy body disease in North America...
  2. ncbi In vivo silencing of alpha-synuclein using naked siRNA
    Jada Lewis
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Mol Neurodegener 3:19. 2008
    ..Genetic variability in SNCA contributes to risk of idiopathic Parkinson's disease (PD), possibly as a result of overexpression. SNCA downregulation is therefore a valid therapeutic target for PD...
  3. ncbi Genetic association study of synphilin-1 in idiopathic Parkinson's disease
    Ronny Myhre
    Department of Laboratory Medicine, Children s and Women s Health, Norwegian University of Science and Technology, Trondheim, Norway
    BMC Med Genet 9:19. 2008
    ..In the present study, we have investigated whether common variability in synphilin-1, including coding substitutions are genetically associated with disease pathogenesis...
  4. ncbi Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications
    Matt Farrer
    Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Ann Neurol 55:174-9. 2004
    ..The profound implications of alpha-synuclein overexpression for idiopathic synucleinopathies are discussed...
  5. ncbi LRRK2 mutations in Parkinson disease
    M Farrer
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Neurology 65:738-40. 2005
    ..Thus LRRK2 mutations only rarely cause idiopathic PD...
  6. ncbi Genetics of Parkinson disease: paradigm shifts and future prospects
    Matthew James Farrer
    Morris K Udall Parkinsons Disease Research Center of Excellence, Birdsall Building, Mayo Clinic, Department of Neuroscience, 4500 San Pablo Road, Jacksonville, Florida 32224, USA
    Nat Rev Genet 7:306-18. 2006
    ..Neuroprotective therapies can now be designed to slow or halt disease progression in affected subjects and asymptomatic carriers...
  7. ncbi DCTN1 mutations in Perry syndrome
    Matthew J Farrer
    Division of Neurogenetics, Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, USA
    Nat Genet 41:163-5. 2009
    ..Our findings show that DCTN1 mutations, previously associated with motor neuron disease, can underlie the selective vulnerability of other neuronal populations in distinct neurodegenerative disorders...

Research Grants6

  1. Mapping a Gene for Parkinsons Disease in Norway
    Matthew Farrer; Fiscal Year: 2005
    ..We will explore the utility of haplotype tagging (htSNPs) to capture disease-association (Aim 3). Identification of the PD-susceptibility gene will be confirmed in US samples and functionally assessed. ..
  2. Genetic Analysis of Tau H1 in Parkinsonism
    Matthew Farrer; Fiscal Year: 2006
    ..abstract_text> ..